The smoking cessation pill for vaping, known as varenicline, has emerged as a beacon of hope in the fight against nicotine addiction among teens and young adults.Research from Mass General Brigham reveals that participants aged 16 to 25 who utilized this FDA-approved treatment were over three times more likely to successfully quit vaping compared to those who only received placebo and behavioral counseling.